-
Mashup Score: 1Perioperative Pembrolizumab Wins Approval in Europe for Resectable NSCLC at High Risk of Recurrence - 9 hour(s) ago
The European Commission has approved neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, for high-risk, resectable NSCLC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Several patients with TP53 Y220C–mutated ovarian cancer experience tumor shrinkage following treatment with rezatapopt in the phase 1/2 PYNNACLE study.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 56
Correlations of overall response rate and progression-free survival with overall survival were generally moderate in this pooled analysis. The findings support routine analysis of mature overall survival data, where feasible, in first-line randomised trials of ICIs for metastatic NSCLC.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Practices are on the cusp of better understanding small cell lung cancer that in turn can help to advance treatment strategies for patients, says Gregory Peter Kalemkerian, MD.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 21ESMO Pocket Guidelines & Mobile App - 3 day(s) ago
ESMO’s mobile app: “ESMO Cancer Guidelines” features six titles each one providing the essential recommendations on a specific topic.
Source: www.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet-
Just out 📢 The ESMO Interactive Guidelines App now includes the newly-updated ESMO Lung & Chest Cancers Pocket Guideline, the easily-accessible, abridged version of the ESMO Clinical Practice Guideline. Available for both iOS and Android devices 🔗 https://t.co/pKmD5VqhyY #LCSM https://t.co/o61GaV2JEZ
-
-
Mashup Score: 83Detection of tumor DNA in bronchoscopic fluids in peripheral non small cell lung cancer: a proof-of-concept study - 6 day(s) ago
The detection of tumor DNA in the supernatant of guide sheath flush fluid collected during r-EBUS bronchoscopy represents a sensitive and complementary method for genotyping non-small cell lung cancer.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
Categories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 11New ADCs bring new questions in EGFR NSCLC and beyond - 9 day(s) ago
Antibody drug conjugates (ADCs) represent one of the fastest growing therapeutic drug classes in solid tumor oncology. The ability to combine highly potent payload moieties with monoclonal antibodies selective for tumor specific antigens has shifted our approach in treating patients with multiple different tumor types, including non-small cell lung cancer (NSCLC). Currently three ADCs in NSCLC have received accelerated approval or breakthrough therapy designation from the FDA, including trastuzumab deruxtecan (T-DXd) for HER2-mutated NSCLC, telisotuzumab vedotin (Teliso-V) for NSCLC with MET overexpression, and patritumab deruxtecan (HER3-DXd) for EGFR-mutated NSCLC.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 148Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer - A Systematic Review - 11 day(s) ago
Uncommon EGFR mutations represent a rare subgroup of non-small cell lung cancer. Data on the efficacy of different generations of tyrosine kinase inhibitors (TKIs) in these rare mutations is scattered and limited to mostly retrospective small cohorts, as these patients were usually excluded from clinical trials.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Overview of the Mechanism of Action of MK-1084 - 11 day(s) ago
Carlos Rojas, MD, discusses the mechanism of action of MK-1084, a selective KRAS G12C inhibitor.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
Perioperative Pembrolizumab Wins Approval in Europe for Resectable NSCLC at High Risk of Recurrence @peters_solange @CHUVLausanne #lcsm https://t.co/E6wDflc0rO